Understanding immune responses in severe dengue infections in children
Official title: Immune responses associated with severe disease in patients with primary dengue infection
Funded at Emory University · NIH-11000009 · Data updated 2026-11-12
This study is looking at how children's immune systems react to dengue infections, especially to understand the differences between mild and severe cases, which could help improve treatments and vaccines for kids under 11.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 10, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $605,852 |
| NIH project number | 1R01AI186371-01 |
| Project ID | NIH-11000009 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 11 years old who are experiencing primary dengue infections.
✕Less likely to help
Patients with secondary dengue infections or those outside the age range of 0-11 years may not benefit from this research.
What this research studies
This research investigates how the immune system responds to primary dengue infections, particularly in children under 11 years old. It aims to identify differences in immune responses between severe primary and secondary dengue infections, focusing on the roles of specific immune cells and antibodies. By conducting comprehensive studies in India, the research seeks to fill knowledge gaps regarding the pathogenesis of severe dengue, which is crucial as the disease spreads to new areas. The findings could lead to improved clinical management and vaccine development.
Why it matters
Potential benefit: If successful, this research could lead to better treatment strategies and vaccines for dengue, particularly for children experiencing severe disease.
How similar studies have gone: Previous research has shown significant insights into secondary dengue infections, but this investigation into primary infections is relatively novel and untested.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Kaja, Murali Krishna — Emory University
- Study coordinator: Kaja, Murali Krishna
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.